In the latest quarter, 7 analysts provided ratings for Guardant Health (NASDAQ:GH), showcasing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish
Total Ratings	6	1
Last 30D	1	0
1M Ago	1	0
2M Ago	2	1
3M Ago	2	0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $34.29, a high estimate of $44.00, and a low estimate of $28.00. This current average represents a 6.69% decrease from the previous average price target of $36.75.

price target chart

Analyzing Analyst Ratings: A Detailed Breakdown

A clear picture of Guardant Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Matthew Sykes	Goldman Sachs	Raises	Buy	$32.00	$28.00
Subbu Nambi	Guggenheim	Announces	Buy	$36.00	-
Kyle Mikson	Canaccord Genuity	Raises	Buy	$38.00	$30.00
Tycho Peterson	Jefferies	Announces	Buy	$32.00	-
Mason Carrico	Stephens & Co.	Maintains	Overweight	$44.00	$44.00
Kyle Mikson	Canaccord Genuity	Lowers	Buy	$30.00	$45.00
Alex Nowark	Craig-Hallum	Announces	Buy	$28.00	-

Key Insights:

Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Guardant Health. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Guardant Health compared to the broader market.
Price Targets: Delving into movements, analysts provide estimates for the future value of Guardant Health's stock. This analysis reveals shifts in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Guardant Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Guardant Health analyst ratings.

Unveiling the Story Behind Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health: A Financial Overview

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Guardant Health displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 30.9%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Guardant Health's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -68.24%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -101.32%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.59%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 19.73, caution is advised due to increased financial risk.

Analyst Ratings: Simplified

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Guardant Health: Insights From 7 Financial Analysts